News Category
Telomir Pharmaceuticals' Telomir-Zn demonstrated growth inhibition in human and canine osteosarcoma models, potentially opening a new translational pa...
Kairos Pharma's CEO presentation at a major investment conference underscores the clinical progress of its lead candidate ENV-105, which aims to rever...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial marks a pivotal step toward a novel therapy that could repair myelin, potentially transfo...
Nutriband received a USPTO Notice of Publication for trademarks related to its abuse-deterrent fentanyl patch, moving closer to full trademark protect...
Quantum BioPharma's Lucid-MS candidate for progressive multiple sclerosis draws a 'Buy' rating from Rodman & Renshaw, highlighting its potential to ad...
Earth Science Tech's acquisition of Zoolzy LLC enhances its compounding pharmacy operations by securing cost-effective APIs and finished FDA-approved ...
DuLac Farmaceutici is accelerating its U.S. expansion by launching products on OneLavi and preparing for ECRM retail meetings, leveraging Amazon succe...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate into preclinical development, signaling progress in its oncology pipeline and ...
Onco-Innovations has signed a non-binding LOI with Ifowonco Informatics to potentially gain exclusive rights to a small-molecule LAG-3 inhibitor progr...
Earth Science Tech's acquisition of Zoolzy positions the company to improve profit margins through competitive API pricing and enter the veterinary ma...
SCHOTT Pharma's parent group's updated climate targets, validated by the SBTi, introduce an absolute Scope 3 reduction target, signaling a strategic s...
Helus Pharma reports progress in its Phase 3 pivotal trials for HLP003 in major depressive disorder, with topline data expected in Q4 2026, and advanc...
VERAXA Biotech's VXA-222 bispecific ADC program advances past discovery, and the company strengthens its IP with new patent filings, underscoring its ...
Tonix Pharmaceuticals announced FDA feedback supporting its adaptive Phase 2 field study for TNX-4800, a long-acting monoclonal antibody aimed at prev...
VERAXA Biotech announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, moving the p...
VERAXA Biotech AG appoints Christoph Erkel as CSO to lead development of its BiTAC platform for solid tumor therapies, signaling a strategic push towa...
NanoViricides announced a $3.8 million registered direct offering to a single institutional investor, providing capital to advance its broad-spectrum ...
VERAXA Biotech AG (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as Chief Scientific Officer, effective immediately, to lead the ...
VERAXA Biotech has obtained Scientific Advice from Germany's Paul-Ehrlich-Institute supporting the development strategy for its lead BiTAC(R)-TCE prog...
VERAXA Biotech AG received Scientific Advice from Germany's Paul-Ehrlich-Institute, clarifying its development strategy for the BiTAC-TCE platform, wi...
Siegfried appoints Eduardo Montanha as COO to lead combined Drug Substances and Drug Products operations, enhancing end-to-end solutions and global su...
NextPlat Corp's planned acquisition of an independent pharmacy in rural Florida for $1.5 million aims to expand its PharmcoRx footprint into an unders...
Onco-Innovations Limited announced the successful completion of an analytical reference standard program for its lead oncology candidate ONC010, a key...
VERAXA Biotech has initiated cell line development for its lead BiTAC T-cell engager program in partnership with ATUM, marking a key milestone toward ...
The global sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036, driven by chronic disease p...
VERAXA Biotech provided a corporate update detailing advancements in its BiTAC platform, including four T-cell engager programs and plans to monetize ...
VERAXA Biotech has begun cell line development for its BiTAC T-cell engager program, leveraging ATUM's Leap-In Transposase technology to advance a nov...
The article discusses how VERAXA Biotech AG's antibody engineering platform aligns with strong deal activity in ADCs and T-cell engagers, similar to t...
Ace Therapeutics announces end-to-end preclinical analgesic drug development services featuring validated in vivo and in vitro pain models, target-bas...
Medios AG is closing its Aschaffenburg facility and consolidating production at other sites to improve profitability, reflecting the ongoing margin pr...
Helus Pharma announced fiscal 2026 financial results, highlighting that its Phase 3 APPROACH trial for HLP003 in major depressive disorder has surpass...
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction plant and an integrated contrast drug man...
Knight Therapeutics repaid its $60 million revolving credit facility used to fund the Paladin acquisition, demonstrating strong operational cash flow ...
Voyageur Pharmaceuticals is assessing potential locations in Oklahoma and Texas for a vertically integrated contrast media plant, aiming to reduce cos...
Earth Science Tech Inc. has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy ecosystem, emphasizing...
Voyageur Pharmaceuticals has submitted a multi-year exploration permit application for its Frances Creek barite project, aiming to advance a feasibili...
Voyageur Pharmaceuticals raised C$5,005,278 through a non-brokered private placement to fund FDA licensing for its barium contrast products, regulator...
Kairos Pharma Ltd. plans to acquire worldwide rights to a Phase 1-ready oral c-MET kinase inhibitor, expanding its oncology pipeline and advancing cli...
Quantum BioPharma's lead drug candidate Lucid-MS targets mobility loss in multiple sclerosis by addressing nerve damage, while its commercial product ...
Quantum BioPharma Ltd. progresses its differentiated multiple sclerosis therapy Lucid-MS into Phase 2 planning, supported by strong financial runway a...
Redwood AI Corp. announced DTC eligibility for its common shares to simplify U.S. trading and enhance liquidity, along with engaging InvestorBrandNetw...
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol-based formulations, is featured in a CityBiz Q&A with founder Mu...
Sino Biological's new cell-free protein synthesis kit enables ultra-fast antibody production in 3 hours, integrating with AI-driven high-throughput sc...
NanoViricides reported progress on its broad-spectrum antiviral NV-387, including regulatory approval for Phase II MPox trials in the DRC and FDA orph...
NanoViricides has priced a $2 million registered direct offering with an institutional investor, providing capital to advance its broad-spectrum antiv...
Lantern Pharma's $4.4 million registered direct offering, with potential additional proceeds from warrants, underscores investor confidence in its AI-...
Tonix Pharmaceuticals announced its participation in two upcoming investor conferences, highlighting its commercial progress and pipeline developments...
Lantern Pharma's expansion of its predictBBB platform into a Large Quantitative Model offers researchers a real-time web-based tool for generating com...
